“脱敏疫苗”治疗过敏性鼻炎,对身体是否有害

2017-04-17 蔺林 澎湃新闻

很多人对过敏性鼻炎的脱敏治疗方式有疑问,这些疑问中有两个比较典型,其一是,进行脱敏治疗的疫苗对身体是否有害?其二是,脱敏治疗过程中产生的新抗体对身体是否有副作用?何为“脱敏治疗”先来了解一下脱敏治疗,就拿过敏原尘螨来说吧。用于进行脱敏治疗的尘螨是在严格流程下生产出来的疫苗,其实质是尘螨的浸出液,就是把尘螨放到某种溶液里进行浸泡,待溶液中某些蛋白达到一定浓度时,便收集该溶液,按标准流程生产出过敏原疫

很多人对过敏性鼻炎的脱敏治疗方式有疑问,这些疑问中有两个比较典型,其一是,进行脱敏治疗的疫苗对身体是否有害?其二是,脱敏治疗过程中产生的新抗体对身体是否有副作用?

何为“脱敏治疗”

先来了解一下脱敏治疗,就拿过敏原尘螨来说吧。用于进行脱敏治疗的尘螨是在严格流程下生产出来的疫苗,其实质是尘螨的浸出液,就是把尘螨放到某种溶液里进行浸泡,待溶液中某些蛋白达到一定浓度时,便收集该溶液,按标准流程生产出过敏原疫苗。

它与普通的病毒疫苗不同,对人体没有感染的风险,只是在低浓度状态下通过皮下或者舌下进入身体,被局部的免疫系统细胞摄入,通过人体的严格流程,产生出某种新抗体,这种新抗体通过局部血液循环,弥散到过敏的部位,与原来鼻黏膜中高浓度的过敏抗体相结合,使过敏抗体失去激活鼻黏膜下肥大细胞的能力。肥大细胞没有激活,就不会释放炎症物质而引起鼻腔里过敏反应。也就是说,患有过敏性鼻炎的人就不会出现打喷嚏、流清涕、鼻塞和鼻痒的典型症状。

这就是脱敏治疗的大致过程。用专业一点的话来说,就是用低剂量的过敏原使你的身体逐渐对其产生耐受,待再次碰到高浓度的过敏原时,就不会产生强烈的过敏反应。

“脱敏疫苗”对身体是否有害

由此看来,进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。当然,也有某些特殊的个体会产生强烈的全身过敏反应,如过敏性休克。这种情况曾经见于皮下注射的脱敏治疗方式,而舌下含服的方式尚未见报道。

舌下含服的不良反应主要是,某些患者开始治疗时会出现嘴唇水肿、口腔溃疡等局部过敏反应,偶尔会出现腹痛、腹泻,待身体对治疗的浓度耐受后,这些不良反应即消失。

新抗体是否有副作用

脱敏治疗过程中产生的新抗体对身体是否有副作用?

脱敏治疗产生出来的新抗体是专门针对患者本身的过敏抗体的,也就是说,具有特异性,一般只会与过敏抗体结合而起作用,不会与体内其他无关的分子或细胞发生作用。就像拼图一样,这个形状的拼块只会与该形状的缺损吻合,不会连到其他缺损上。

综上所述,即便过敏性鼻炎脱敏治疗用的疫苗使身体产生过敏反应,甚至是全身性过敏反应,都是暂时的,而且都有完善的应对策略。

沿用百年的脱敏治疗方法挽救了很多人的生命,更让人类的生活质量有了显着提高,而且这种治疗方式也是在不断创新和改进,明天它将为更多的患者解决病痛。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2023-07-12 1238bd83m05暂无昵称 来自内蒙古

    你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-27 往日如昨

    进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-24 往日如昨

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-21 刘煜

    学习了谢谢分享。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-19 虈亣靌

    全程参与实验,即学即用,多次实践,确保掌握所学技术。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-19 䖝二

    息息相关

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-18 jin321

    注意

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-18 半夏微凉

    学习了,谢谢分享!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2147683, encodeId=f093214e683f5, content=你这个文章里,关于脱敏机制的原理描述是错误的,目前免疫学的主流看法是多次少量脱敏用来调整免疫T细胞,达到一个适应性效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1292417434, createdName=1238bd83m05暂无昵称, createdTime=Wed Jul 12 18:05:06 CST 2023, time=2023-07-12, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2046823, encodeId=a9452046823ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Apr 25 03:51:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191055, encodeId=1cfd19105552, content=进行脱敏治疗的这种疫苗就是低浓度的过敏原,对人体的所谓“危害”就是产生微弱的过敏反应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Apr 27 10:03:01 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190083, encodeId=d3de1900830d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Apr 24 08:45:40 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189224, encodeId=61c91892242d, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Apr 21 06:00:49 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188775, encodeId=4eb7188e757d, content=全程参与实验,即学即用,多次实践,确保掌握所学技术。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Apr 19 10:59:34 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188619, encodeId=80f318861976, content=息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:05:07 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188428, encodeId=f5bb188428e2, content=注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Tue Apr 18 07:52:17 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188380, encodeId=a2b3188380b3, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Apr 18 07:10:52 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188347, encodeId=78e618834ebd, content=过敏体质的孩子伤不起啊,幸亏有了脱敏疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6hq2LmWPOViahibFAUK6qIgYDYRCuDHfj1nJkb5WHIZEj8BwULbciboiblfEG1rA78tX3E0Hp7iaCAg3/0, createdBy=f37b2049644, createdName=virya, createdTime=Tue Apr 18 02:31:39 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-18 virya

    过敏体质的孩子伤不起啊,幸亏有了脱敏疗法

    0

相关资讯

Sci Rep:在过敏性鼻炎(AR)中,维他命D3可以通过抑制微小RNA-17-92来改善特异性免疫疗法疗效

辅助性T细胞(Th2)极化在大多数免疫缺陷中起到重要的作用。然而,如何补救和调停已经形成的Th2极化到目前为止所知有限。已经发表的资料表明微小RNA-17-93簇与异常的免疫响应有关,25种维他命D3在体内可以调控多种生物活性。最近,研究人员提出并检测了这样的一个假设,即VD3在Th2响应中,可以促进特异性免疫疗法(SIT)的疗效。研究人员发现,用SIT或者VD3处理,可以减轻AR症状,并且可以降

Sci Rep:中性粒细胞的子分类对过敏性鼻炎的作用

重新审视之前对过敏性鼻炎的观念对于满足当今过敏性鼻炎的医学挑战是需要的。以前,不论是过敏季节高峰病人承受过敏症状,还是病人报告并未出现过敏症状,中性粒细胞都被认为是鼻子中的同种细胞群。新的数据资料显示,中性粒细胞可以被分为不同的子分类,并且不同的分类在炎症反应中有不同的角色。最近,研究人员发现,和正常对照组比较,花粉季节过敏性鼻炎病人的外周血、鼻骨活组织切片和鼻腔灌洗液体(NAL)中中性粒细胞的水

花粉刺激易诱发过敏性鼻炎,中医针灸按摩可防治

春季乍暖还寒,又到了外出踏青的好时节。然而,对于过敏性体质的人来说,花粉、日光等过敏原的刺激很容易诱发过敏性鼻炎。从中医角度讲,过敏性鼻炎的病因病机是什么?除了西药外,还有什么中医疗法可以防治过敏性鼻炎?过敏原有哪些过敏性鼻炎,是以突然和反复发作的鼻痒、喷嚏、流清涕、鼻塞等为特征的一种常见、多发性鼻病。中医称为鼻鼽又称鼽嚏。过敏性鼻炎的发生须具备两个条件:一、病人为过敏体质(即特应性个体),其黏膜

指南专题:变应性鼻炎如何诊断与治疗?答案在这里!

最是一年春好处,阳春三月正是外出春游赏花的好时节。然而,对于过敏性鼻炎的患者来说,却是一年中最无法言说的痛:整日顶着通红的鼻头,不停打着喷嚏,擦着鼻涕,“赏春”变成了“伤春”! 每到现在的这个季节,门诊的过敏性鼻炎患者会激增,大多数患者都是外出时吸入过敏源所导致的季节性过敏性鼻炎。过敏性鼻炎又称变应性鼻炎,它的发生需要同时具备三个条件,即特应性个体(过敏体质的人)、过敏源(主要包括花粉、植物毛絮

JAMA:舌下草花粉免疫治疗对过敏性鼻炎真的有用么?

舌下免疫治疗和皮下免疫治疗在季节性过敏性鼻炎中有一定疗效。皮下免疫和舌下免疫连续治疗三年,至少可以改善治疗后2年的症状。近期,一项发表在权威杂志JAMA上的研究旨在评估使用草花粉舌下免疫治疗2年能否改善3年的鼻应答过敏反应。这是一项随机双盲安慰剂对照试验,3个平行组研究在伦敦帝国理工学院的单一学术中心进行,试验对象为中度至重度季节性过敏性鼻炎成人患者(干扰日常活动或睡眠)。第一次招募时间是2011

Molecules:传统中医药参芪通过调控肥大细胞脱粒和Th1/Th2细胞因子平衡对抗过敏性鼻炎的影响

参芪是一种传统的中草药,并且被广泛的用于对过敏性鼻炎(AR)的治疗。最近,研究人员对参芪的抗过敏性鼻炎的活性和其潜在的分子机制进行了研究。研究人员将卵清蛋白(OVA)诱导的过敏性鼻炎小鼠模型用来评估参芪的抗过敏性鼻炎活性,并利用小鼠嗜碱性白血病(RBL-2H3)细胞来检测参芪对免疫球蛋白E调控的细胞脱粒的影响。研究人员通过分离脾脏淋巴球,并通过蛋白免疫印迹技术检测转录因子和ELISA技术检测细胞因